

LETTER TO THE JOURNAL

Disclosing the true impact of screening endoscopy in colorectal cancer prevention

Preprint: <https://doi.org/10.1101/2022.11.22.22282622>

Randomized trials, cohort and modeling studies have consistently demonstrated a major impact of screening endoscopies on reducing colorectal cancer (CRC) incidence and mortality [1]. Over time, CRC mortality starts to be lower in those who underwent screening compared to those who did not due to earlier detection of prevalent, preclinical (asymptomatic) cases and lowering incidence through removing precancerous lesions. By contrast, measured incidence shows an initial apparent increase in the screening group due to the detection of preclinical (i.e., already prevalent) cancer. Only after around 4–6 years of follow-up, the measured cumulative incidence also starts to be lower in the screening group due to later manifestation of the initially preclinical cases in the control group and removal of precancerous lesions in the screening group [2–6].

However, measured incidence rates do not reflect true incidence rates as they are a mix of truly incident cases and cases that are already prevalent in the preclinical stage at baseline. As screening endoscopies cannot prevent prevalent CRC cases (but only remove precursor lesions at risk of developing into CRC), the commonly measured and reported effects on CRC incidence do not quantify the true endoscopy impact on CRC incidence, i.e., the impact on preventing newly developing CRC cases. In the present study, we sought to quantify the true impact of screening endoscopy on CRC incidence.

First, by re-calibrating the Colorectal Cancer Multistate Simulation Model (COSIMO), a thoroughly validated modeling approach, we replicated the Screening for COlon REctum trial (SCORE), a large, randomized trial ($n = 34,292$) examining the effect of a single flexible sigmoidoscopy in reducing CRC incidence and mortality by matching the numbers of simulated subjects and allocation

per group with reported baseline numbers by sex and age, also taking into account colonoscopy referral and background endoscopy use [5]. Further details are provided in the Supplementary Material and Methods. The primary validation objective was the agreement between modeled and in SCORE reported incidence rate ratios (in the following: incidence rate ratio [unadjusted], $IRR_{Unadjusted}$). The results were considered consistent if modeled estimates were within the 95% confidence intervals of the corresponding outcomes reported for SCORE.

Then, to determine the impact of prevalent preclinical CRCs on $IRR_{Unadjusted}$, we calculated the adjusted IRR (incidence rate ratio (adjusted), $IRR_{Adjusted}$, excluding prevalent CRCs at baseline) for the screening versus control groups by omitting the sex- and age-specific number of cases arising from prevalent preclinical CRC from the model calculation of IRRs for each year of follow-up.

Incidence rates and $IRR_{Unadjusted}$ predicted by COSIMO followed analogous patterns as those reported for SCORE (Figure 1A), i.e., in the first six years after randomization, the cumulative incidence in the screening group was higher than in the control group. All primary validation targets were reached (Supplementary Figure S1).

Excluding prevalent preclinical CRC at baseline markedly changed the numbers of detected CRC cases and incidence rates. The relative share of prevalent screen-detected cases among all detected cases was higher in the screening group than in the control group but exceeded 50% in the initial five years of follow-up in both groups (Figure 1B). The share of prevalent cases from all cumulatively reported cases diminished with increasing length of follow-up, but even after 15 years of follow-up, it was still as high as 22.5% and 17.5% in the screening and control groups, respectively.

In the intention-to-screen analysis, unadjusted/adjusted risk reductions after 8, 11 and 15 years of follow-up were 16%/31%, 20%/28%, and 21%/25%, respectively (Supplementary Table S1, Figure 1C). In per-protocol analyses, respective unadjusted/adjusted risk reductions were 28%/54%, 34%/49%, and 35%/44% (Figure 1D). Even though both

Abbreviations: COSIMO, Colorectal Cancer Multistate Simulation Model; CRC, Colorectal cancer; IRR, Incidence rate ratio; NordICC, Nordic-European Initiative on Colorectal Cancer trial; RCT, Randomized controlled trial; SCORE, Screening for COlon REctum trial.

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial-NoDerivs](https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2024 The Authors. *Cancer Communications* published by John Wiley & Sons Australia, Ltd. on behalf of Sun Yat-sen University Cancer Center.




FIGURE 1 Outcomes in the actual and simulated SCORE trial. (A) Cumulative CRC incidence over time in screening versus control arms in the actual SCORE trial ('SCORE-Published'), a reproduced SCORE trial by the simulation tool COSIMO ('COSIMO-Unadjusted'), and a reproduced SCORE trial by the simulation tool COSIMO additionally adjusted by excluding prevalent CRC at baseline in both arms ('COSIMO-Adjusted'); (B) Cumulative numbers of CRC over time in screening versus control arms in the reproduced SCORE trial by the simulation tool COSIMO, broken down into truly incident cases (i.e., developed after baseline) and actually prevalent cases (i.e., preclinical but asymptomatic CRC already present at baseline); (C) Risk ratios over time for the intention-to-screen analysis (CRC incidence rate for the screening group (as invited) divided by the CRC incidence rate for the control group); (D) Risk ratios over time for the per-protocol analysis (CRC incidence rate for the screening group (only including subjects who used actually used screening) divided by the CRC incidence rate for the control group). Definitions: 1. Truly incident cases: New cases of CRC that developed during the study period, that is, did not exist before the start of the study and emerged as new occurrences during the period of observation. 2. Actually prevalent cases: These refer to the CRC cases that were already present but in a preclinical stage (asymptomatic) at the beginning of the study. They were not new occurrences during the study period but were existing cases that were detected through screening procedures (and could thus not be prevented by screening). Abbreviations: COSIMO, Cancer Multistate Simulation Model; CRC, Colorectal Cancer; SCORE, Screening for COlon RECTum trial.

$IRR_{Unadjusted}$ and $IRR_{Adjusted}$ were lower than 1, indicating a protective effect of screening, after 5 or more years of follow-up, and the difference between $IRR_{Unadjusted}$ and $IRR_{Adjusted}$ diminished over time, adjusted incidence reduction was still underestimated by 16% and 20% in intention-to-screen and per-protocol analyses, respectively, even after 15 years of follow-up.

The effectiveness of screening sigmoidoscopy to reduce CRC risks has been studied in four randomized controlled trials (RCTs), with reported cumulative incidence reductions after median 14-17 years of follow-up ranging from 18% to 26% in the intention-to-screen analysis and from 33% to 35% in the per-protocol analysis [2-5]. All RCTs

have in common that the preventive effect of screening sigmoidoscopy (by removal of precancerous lesions following their endoscopic detection) mostly manifested after 4-6 years. Although the reason for this behavior (i.e., the dominance of screen-detected prevalent cancers, which could not any longer be prevented in the first years of follow-up) has been previously noted [7, 8], to our knowledge, no attempt has been made to quantify the impact of these prevalent cancers, and their relative contribution to the overall reported incidence reduction remained unclear.

This modeling study adds such quantification of the true impact of endoscopy on CRC incidence reduction

to the literature. The findings indicate that the preventive potential of screening endoscopy is likely much larger than previously reported, most notably within the first 10 years after screening and still not fully discernable even after 15 years of follow-up. Excluding prevalent cancers had several implications. First, there was no characteristic crossing of incidence curves after 4–6 years [2–5], and the screening group was strongly favored from the beginning. Second, while the $IRR_{Unadjusted}$ tended to improve in favor of screening with increasing duration of follow-up, $IRR_{Adjusted}$ suggested the strongest difference between screening versus control early after screening. Still, strong differences were seen with increasing follow-up duration. Third, while $IRR_{Adjusted}$ were consistently more favorable towards screening than $IRR_{Unadjusted}$, the magnitude of the underestimation strongly depended on the time of follow-up (e.g., in intention-to-screen analyses, the “adjusted” incidence reduction by screening was 29 per cent points higher after 5 years, but only 4 per cent points higher after 15 years (Supplementary Table S1), illustrating the diminishing impact of prevalent preclinical cases with increasing follow-up durations.

Long-term outcomes from several RCTs on the effects of screening colonoscopy are still pending. Initial results from the Nordic-European Initiative on Colorectal Cancer trial (NordICC) were recently published [6]. However, given that follow-up so far was limited to 10 years, results are preliminary [9]. Our results suggest that the underestimation of true incidence reduction by the inclusion of a high proportion of prevalent cases may be substantial. The combined body of evidence from case-control, cohort and simulation studies suggests that the preventive potential of colonoscopy may even be larger than for sigmoidoscopy [10].

In summary, in randomized trials, the true impact of screening endoscopy on reducing CRC incidence is partly masked by the inclusion of preclinical (i.e., prevalent CRCs) at baseline. The relative share of such prevalent cases detected by screening from all detected cases strongly depends on the length of follow-up and diminishes over time. Excluding prevalent cancers at baseline in a replicated version of the randomized SCORE trial suggests that the “true” incidence reduction by screening sigmoidoscopy is strongly underestimated in the first 10 years of follow-up and still underestimated by 16%–20% even after 15 years compared to published estimates. Thus, the preventive effect of screening endoscopy is likely much stronger and manifests much earlier than previously reported. Published findings of randomized screening trials significantly underestimate the true preventive effects of screening endoscopy.

AUTHOR CONTRIBUTIONS

Hermann Brenner and Thomas Heisser designed the study and developed the methodology. Thomas Heisser conducted the statistical analyses and drafted the manuscript. All authors critically reviewed the manuscript, contributed to its revision, and approved the final version submitted. The researchers are independent from funders. All authors had full access to all of the data used for the study and can take responsibility for the integrity of the data and the accuracy of the data analysis.

ACKNOWLEDGEMENTS

The authors have nothing to report.

CONFLICT OF INTEREST STATEMENT

The authors declare no conflicts of interest.

FUNDING INFORMATION

Financial support for this study was provided in part by grants from the German Federal Ministry of Education and Research (grant numbers 01GL1712 and 01KD2104A) and the German Cancer Aid (grant number 70114735). The funding agreement ensured the authors' independence in designing the study, interpreting the data, writing, and publishing the report.

DATA AVAILABILITY STATEMENT

All analyses relevant to the study are included in the article or uploaded as supplementary information. The model source code is available from <https://www.dkfz.de/en/klinepi/download/index.html>. Further information is available from the corresponding author upon request.

ETHICS APPROVAL

Not required.

CONSENT TO PARTICIPATE

Not required.

CONSENT FOR PUBLICATION

Not required.

Thomas Heisser¹ 

Carlo Senore²

Michael Hoffmeister¹

Lina Jansen³

Hermann Brenner^{1,4,5} 

¹Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Baden-Württemberg, Germany

²*Epidemiology and Screening Unit, Reference Centre for Epidemiology and Cancer Prevention, University Hospital Città della Salute e della Scienza, Turin, Piedmont, Italy*

³*Epidemiological Cancer Registry Baden-Württemberg, German Cancer Research Center (DKFZ), Heidelberg, Baden-Württemberg, Germany*

⁴*Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Baden-Württemberg, Germany*

⁵*German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Baden-Württemberg, Germany*

Correspondence

Thomas Heisser, Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 581, Heidelberg, 69120, Baden-Württemberg, Germany.
Email: t.heisser@dkfz.de

ORCID

Thomas Heisser  <https://orcid.org/0000-0002-1348-3350>

Hermann Brenner  <https://orcid.org/0000-0002-6129-1572>

REFERENCES

1. Kanth P, Inadomi JM. Screening and prevention of colorectal cancer. *BMJ*. 2021;374:n1855.
2. Atkin W, Wooldrage K, Parkin DM, Kralj-Hans I, MacRae E, Shah U, et al. Long term effects of once-only flexible sigmoidoscopy screening after 17 years of follow-up: the UK Flexible Sigmoidoscopy Screening randomised controlled trial. *Lancet*. 2017;389(10076):1299–1311.
3. Holme O, Loberg M, Kalager M, Bretthauer M, Hernan MA, Aas E, et al. Long-Term Effectiveness of Sigmoidoscopy Screen-

ing on Colorectal Cancer Incidence and Mortality in Women and Men: A Randomized Trial. *Ann Intern Med*. 2018;168(11):775–782.

4. Miller EA, Pinsky PF, Schoen RE, Prorok PC, Church TR. Effect of flexible sigmoidoscopy screening on colorectal cancer incidence and mortality: long-term follow-up of the randomised US PLCO cancer screening trial. *Lancet Gastroenterol Hepatol*. 2019;4(2):101–110.
5. Senore C, Riggi E, Armaroli P, Bonelli L, Sciallero S, Zappa M, et al. Long-Term Follow-up of the Italian Flexible Sigmoidoscopy Screening Trial. *Ann Intern Med*. 2022;175(1):36–45.
6. Bretthauer M, Loberg M, Wieszczy P, Kalager M, Emilsson L, Garborg K, et al. Effect of Colonoscopy Screening on Risks of Colorectal Cancer and Related Death. *N Engl J Med*. 2022;387(17):1547–1556.
7. Segnan N, Armaroli P, Bonelli L, Risio M, Sciallero S, Zappa M, et al. Once-Only Sigmoidoscopy in Colorectal Cancer Screening: Follow-up Findings of the Italian Randomized Controlled Trial—SCORE. *J Natl Cancer Inst*. 2011;103(17):1310–1322.
8. Atkin WS, Edwards R, Kralj-Hans I, Wooldrage K, Hart AR, Northover JMA, et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. *Lancet*. 2010;375(9726):1624–1633.
9. Dominitz JA, Robertson DJ. Understanding the Results of a Randomized Trial of Screening Colonoscopy. *N Engl J Med*. 2022;387(17):1609–1611.
10. Brenner H, Stock C, Hoffmeister M. Effect of screening sigmoidoscopy and screening colonoscopy on colorectal cancer incidence and mortality: systematic review and meta-analysis of randomised controlled trials and observational studies. *BMJ*. 2014;348:g2467.

SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.